FOLH1 and neoplasm: In a follow-up study, 15 TRNT-naïve mCRPC patients with visceral metastases, large tumor burden, and short PSA doubling times were subjected to two cycles of [177Lu]Lu-PSMA-617, at least one of which was given in combination with [225Ac]Ac-PSMA-617.